FDA is warning patients and health care professionals not to use products intended to be sterile produced by North American Custom Laboratories LLC, FarmaKeio Superior Custom Compounding, Richardson, TX, due to a lack of sterility assurance. Administration of a non-sterile drug intended to be sterile may result in serious and potentially life-threatening adverse health consequences including infections and sepsis.
Health care professionals should immediately check their medical supplies, quarantine any drugs intending to be sterile and produced by FarmaKeio Superior Custom Compounding, and not administer or provide them to patients. FDA urges health care professionals who obtained products from this company to make alternative arrangements to obtain medications from sources that adhere to proper quality standards. Patients who have received any drug produced by the company and have concerns should contact their health care professional.
FDA investigators recently inspected FarmaKeio Superior Custom Compounding’s facility located at 1736 N. Greenville Ave., Richardson, TX, and observed conditions that could cause the drugs produced by the company to become contaminated or otherwise pose risks to patients. This company was inspected as a 503A pharmacy compounding facility. FDA recommended the company voluntarily recall all unexpired drugs intended to be sterile and cease sterile operations until the company takes adequate corrective actions. However, the company has not initiated a recall.
To date, FDA is not aware of any reports of illness associated with the use of FarmaKeio Superior Custom Compounding’s drugs.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!